Citius Oncology Reports Promising LYMPHIR Cancer Data
CRANFORD, N.J., June 1, 2026 Citius Oncology has announced encouraging Phase 1 clinical findings evaluating LYMPHIR® (denileukin diftitox-cxdl) in...
antibody-drug conjugate
Advertisement
Ribo’s RBD1119 Moves Into Phase 2 Development for Coronary Artery Disease
SUZHOU, China, May 29, 2026 Suzhou Ribo Life Science and Ribocure Pharmaceuticals (collectively “Ribo”) have announced the submission of...
Gilead Expands Oncology Portfolio With Tubulis Deal
Foster City, California, USA – May 22, 2026 Gilead Sciences, Inc. announced the successful completion of its acquisition of...
Kelun-Biotech Highlights Major NSCLC Data at ASCO 2026
CHENGDU, China, 21 May 2026 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that two registrational studies involving its lead oncology...
Iza-bren Meets Dual Endpoints in Phase III TNBC
REDMOND, Wash. & PRINCETON, N.J., February 26, 2026 SystImmune, Inc. and Bristol Myers Squibb announced positive interim topline results...
Advertisements
Day One Biopharma Acquires Mersana to Advance ADC Pipeline
BRISBANE, CA – November 13, 2025 — Day One Biopharmaceuticals announced a definitive agreement to acquire Mersana Therapeutics in...
Tubulis Secures €344 M Series C to Accelerate ADC Clinical Growth
Munich, Germany, October 30, 2025 — Tubulis GmbH announced the successful second and final closing of its Series C...
Tagworks Advances TGW101 in Phase 1 Trial for Solid Tumors
NIJMEGEN, Netherlands and BOSTON, September 9, 2025 — Tagworks Pharmaceuticals has initiated the third dose level in its ongoing...
Advertisement
